Autolus Reiterates $120M–$135M AUCATZYL 2026 Target Autolus reiterated a $120M–$135M 2026 revenue target for AUCATZYL on Mar. 27, 2026 and said it will expand its pivotal-trial program (Seeking Alpha).

Autolus Reiterates $120M–$135M AUCATZYL 2026 Target: Autolus reiterated a $120M–$135M 2026 revenue target for AUCATZYL on Mar. 27, 2026 and said it will expand its pivotal-trial program (Seeking Alpha). 👈 Read full analysis #Autolus #AUCATZYL #Biotech #Pharmaceuticals #ClinicalTrials

NICE backs NHS use of Autolus' leukaemia CAR-T Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

#haematology #NICE #NHS #leukaemiaCART #Autolus #leukaemia #CARTtherapy #NHSroutinecommissioning #Aucatzyl #BcellALL #acutelymphoblasticleukaemia #relapsedALL #refractoryALL #Bcellprecursoracutelymphoblasticleukaemia #ALL #NICEfinaldraftguidance #HTA #FELIXtrial #NICEguidance
zurl.co/h6OwD

NICE backs NHS use of Autolus' leukaemia CAR-T Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

Hundreds of people with a rare and aggressive form of #leukaemia will be able to access a #CARTtherapy developed by #UK biotech #Autolus after it was recommended for routine commissioning by the #NHS.